REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023

Rhea-AI Summary

REGENXBIO Inc. (RGNX) announced new interim data from trials of its gene therapies RGX-121 and RGX-111 for MPS II and MPS I, respectively. These results will be showcased at the 19th Annual WORLD Symposium™ from February 22-26, 2023, in Orlando, Florida. The company will present three oral and eight poster presentations, including interim analyses from both clinical trials. Additionally, REGENXBIO will host a symposium session on February 24, discussing AAV gene therapy for neuronopathic MPS II. The event underscores REGENXBIO's commitment to advancing gene therapy solutions and enhancing treatment options for rare diseases.

News Market Reaction

+4.67%

1 alert

+4.67% News Effect

On the day this news was published, RGNX gained 4.67%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

• New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of RGX-111 for the treatment of MPS I to be presented

ROCKVILLE, Md., Feb. 17, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and eight poster presentations will be presented at the 19^th Annual WORLDSymposium™ 2023, taking place in Orlando, Florida from February 22 through 26, 2023. The presentations include new interim results from the Phase I/II/III clinical trial of RGX-121 for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome, and the Phase I/II trial of RGX-111 for the treatment of severe mucopolysaccharidosis type I (MPS I).

REGENXBIO will also host a sponsored symposium session, titled "AAV Gene Therapy as a Potential Treatment Modality for Neuronopathic MPS II" on Friday, February 24, 2023, at 11:45 a.m. ET.

The oral presentations will be presented as follows:

Abstract Title: RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in human study (abstract #191)
Presenter: Raymond Wang, M.D., Division of Metabolic Disorders, CHOC Children's Hospital, Department of Pediatrics, University of California, Irvine, CA
Date/Time: Friday, February 24, 2023, 9:24 a.m. ET

Abstract Title: In vitro pharmacology study using retina organoids and retina-on-a-chip of CLN2 patient-derived induced pluripotent stem cells (abstract #311, also available as poster #201)
Presenter: Kwi Hye Kim, Ph.D., Principal Scientist, Preclinical Development at REGENXBIO Inc.
Date/Time: Saturday, February 25, 2023, 2:48 p.m. ET

Abstract Title: RGX-121 gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study (abstract #LB-21)
Presenter: Can Ficicioglu, M.D., Ph.D., Professor of Pediatrics at Perelman School of Medicine at the University of Pennsylvania, Director of the Newborn Metabolic Screening Program and the Lysosomal Storage Diseases Program, Clinical Director of the Metabolic Disease Program Children's Hospital of Philadelphia
Date/Time: Sunday, February 26, 2023, 9 a.m. ET (also available as an ePoster Wednesday, February 22, 2023, 3 p.m. ET)

The poster presentations will be presented as follows:

Abstract Title: Spontaneous seizures associated with cortical interneuron loss in Cln2^R207X mice are ameliorated via gene therapy (abstract #350)
Presenter: Keigo Takahashi, Ph.D. Candidate, Pediatric Storage Disease Lab, Washington University in St. Louis
Date/Time: Thursday, February 23, 2023, 3-4 p.m. ET

Abstract Title: RGX-381 Gene Therapy for the Treatment of Ocular Manifestations of Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease): Overview of Nonclinical Development Program (abstract #LB-17)
Presenter: Gary Chan, Ph.D., Scientist II, Preclinical Development at REGENXBIO Inc.
Date/Time: Thursday, February 23, 2023, 4-5 p.m. ET

Abstract Title: The relationship between the expanded neuronal ceroid lipofuscinosis 2 (CLN2) clinical rating scale for motor function (CLN2 CRS-MX) and GAITRite® parameters (abstract #152)
Presenter: Luca Hagenah, M.D., University Medical Center Hamburg-Eppendorf, Department of Pediatrics, Hamburg
Date/Time: Friday, February 24, 2023, 3-5 p.m.

Abstract Title: Daily living skills on the Vineland Adaptive Behavioral Scale Version 2 (VABS-II) following RGX-121 treatment in participants with neuronopathic Mucopolysaccharidosis Type II (MPS II) (poster #285)
Presenter: Dawn Phillips P.T., M.S., Ph.D., Senior Director of Clinical Outcomes Research at REGENXBIO Inc.
Date/Time: Saturday, February 25, 2023, 3-5 p.m.

Abstract Title: Quantifying and modelling disease progression trajectory for natural history of MPS II (abstract #73)
Presenter: Yoonjin Cho, Ph.D., Senior Director, Biostatistics at REGENXBIO Inc.
Date/Time: Saturday, February 25, 2023, 3-5 p.m.

Abstract Title: RGX-381: First-in-human clinical trial of an investigational AAV9 gene therapy encoding TPP1 for the treatment of ocular manifestations of CLN2 Batten disease (abstract #LB-45)
Presenter: Christina Ohnsman, M.D., Senior Clinical Development Lead at REGENXBIO Inc.
Date/Time: Saturday, February 25, 2023, 3-5 p.m.

Abstract Title: Characterization of retinal degeneration phenotype in classic CLN2 disease using OCT biomarkers and an in vitro retinal model (abstract #261)
Presenter: Christina Ohnsman, M.D., Senior Clinical Development Lead at REGENXBIO Inc.
Date/Time: Saturday, February 25, 2023, 3-5 p.m.

Abstract Title: Loss of visual function associated with photoreceptor degeneration in CLN2 disease (abstract #260)
Presenter: Christina Ohnsman, M.D., Senior Clinical Development Lead at REGENXBIO Inc.
Date/Time: Saturday, February 25, 2023, 3-5 p.m.

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-19th-annual-worldsymposium--2023-301749520.html

SOURCE REGENXBIO Inc.

FAQ

What is the purpose of REGENXBIO's presentations at the WORLD Symposium 2023?

REGENXBIO will present interim data on its gene therapies RGX-121 and RGX-111 for treating MPS II and MPS I, respectively.

When will REGENXBIO present new data at the WORLD Symposium 2023?

REGENXBIO's presentations will occur from February 22 to February 26, 2023.

What are RGX-121 and RGX-111 used to treat?

RGX-121 is developed for treating MPS II, while RGX-111 targets MPS I.

Is REGENXBIO hosting any additional events at the symposium?

Yes, REGENXBIO will host a symposium session on February 24, discussing gene therapy for neuronopathic MPS II.

How many presentations will REGENXBIO have at the WORLD Symposium 2023?

REGENXBIO will have three oral presentations and eight poster presentations.